𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus

✍ Scribed by Joel Schiffenbauer; Bevra Hahn; Michael H. Weisman; Lee S. Simon

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
70 KB
Volume
50
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The American College of Rheumatology res
The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: Measures of overall disease activity
✍ American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosu πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 202 KB πŸ‘ 2 views

## Abstract ## Objective Improved standards for the evaluation of therapeutic interventions in systemic lupus erythematosus (SLE) are needed. The purpose of this study by a committee of the American College of Rheumatology was to define clinically meaningful improvement, no change, or worsening in

Sialic acid–binding Ig-like lectin 1 exp
Sialic acid–binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus
✍ Robert Biesen; Cemal Demir; Fidan Barkhudarova; Joachim R. GrΓΌn; Marta Steinbric πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 257 KB πŸ‘ 1 views

## Abstract ## Objective Type I interferon (IFN) plays a pivotal role in the pathogenesis of systemic lupus erythematosus (SLE) and is therefore considered a potential therapeutic target. This study was undertaken to establish a feasible biomarker for IFN effects with respect to disease activity a